|Articles|November 15, 2017
- BioPharm International-11-15-2017
- Volume 2017 eBook
- Issue 3
Cold Chain: Delivering Vaccines to Patients
Author(s)Amber Lowry
This article explores some of the challenges, services, and technologies that go into ensuring that vaccines are properly temperature controlled and maintain product integrity for delivery to patients.
Advertisement
With advancement in vaccine development comes an urgency to optimize the cold-chain delivery of these increasingly condition-sensitive biological products. This sensitivity has added new degrees of complexity to already complex supply chains and global regulations, resulting in the need for more precise approaches toward transporting vaccines.
Download
eBook.
Article Details
Pharmaceutical Technology and BioPharm International
eBook: Vaccine Development and Manufacturing 2017
November 2017
Pages: 46–49
Citation
When referring to this article, please cite it as A. Lowry, " Cold Chain: Delivering Vaccines to Patients," Pharmaceutical Technology and BioPharm International Vaccine Development and Manufacturing 2017 eBook (November 2017).
Articles in this issue
almost 8 years ago
Designing and Operating Flexible, High-Containment Vaccine Manufacturingalmost 8 years ago
Therapeutic Vaccines Target Cancer and Other Viral-Induced Diseasesalmost 8 years ago
Using Human Challenge Trials to Develop Flu Vaccinesalmost 8 years ago
Moving to Closed Systems for Aseptic Processingalmost 8 years ago
Making Vaccines Accessiblealmost 8 years ago
Accelerating Vaccine Development and ManufacturingNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Everything to Know About Cell and Gene Therapy in 2025
2
Biologics, Obesity, China Top Financial Trends Reshaping Pharma R&D in J.P. Morgan Report
3
CGT Innovations: The Three-Pronged Strategy for Industry Growth (Part 2)
4
Overcoming Funding Challenges and Maintaining Optimism in CGTs (Part 1)
5
